corporate responsibility update ecatur etureli lilly year unt content abo cum ni company demonstrated message ceo nullectia rest commitment responsible lilly key performance indicator ut vellum global qui citizenincluding long blaborectat conducting business ethically transparently history philanthropic contribution cusam greatestoccul contribution society enhancing access medicine however discovering developing developing innovative medicine innovative medicine running supporting strong workplace practice business ethically responsibly lilly around world engaging patient fostering environmental sustainability united nation global compact index report lorem ipsum message ceo message ceo dear reader also provide opportunity employee share expertise community around core lillys vision aim improve global world connecting heart abroad signature global health st century first foremost service initiative one example launched creating medicine help people live longer program sends lilly ambassador year healthier active life also believe twoweek community development assignment business important lillys asia africa central south america commitment united nation global compact ungc reflects core value integrity excellence lilly rank among world charitable company respect people integral donating million cr company since founding year ago charity believe opportunity missed know even improve global health proud present update report highlight bring table expertise chronic disease commitment progress around corporate along financial resource responsibility cr increasingly integrating concept shared u responsibility start treat value way operate using business employee employee play indispensable role expertise help address pressing social need open helping u meet cr commitment turn new opportunity u provide solution health strive encourage maintaining supportive challenge world believe approach respectful working environment put special help create enduring value society lilly emphasis flexibility workplace making individual patient better help honored named diversityincs top patientsas well community broader company working family societiesto thrive lilly corporate responsibility update lorem ipsum message ceo along investing asset expertise example speke united kingdom manufacturing spearhead broad strategic partnership improve facility new process antibiotic production access health care example decreased water usage million liter per yearor percent total usagewhile reducing steam lilly mdrtb partnership offer education usage metric tonsor percent overall use training improved care people fighting deadly change helped save multidrugresistant tuberculosis projected waste stream reduction related initiative lilly ncd partnership launched could push annual saving million also provide million five year fight rising pleased lilly site globally reported burden noncommunicable disease ncds zero landfill status indicating send less developing nation percent generated waste landfill announced lilly truassist easytouse proud accomplishment yet onestop resource patientassistance recognize must make progress still program lilly long offered help people committed behalf everyone obtain lilly medication need lilly thank interest company patient received help program cr update welcome feedback percent increase previous year environmental arena weve set goal limit impact drawing scientific technical business expertise eliminate waste inefficiency wherever possible john c lechleiter phd chairman president chief executive officer november lilly corporate responsibility update loremlilly ipsum lilly fact glance november lilly make medicine help people live longer healthier active life founded th largest pharmaceutical company world around globe forged productive alliance partnership advance capacity develop innovative medicine lower cost world urgent medical need year strong founded employee engaged country clinical country research may research development research conducted development facility lilly long history medical innovation notably treatment infectious disease diabetes depression today portfolio also includes oncology biomedicine emerging market business unit work deliver medicine address unmet need around world additional information usa lly corporate history significant medical breakthrough visit section wwwlillycom country billion worldwide headquartered symbol listed product marketed revenue indianapolis indiana new york stock exchange united state elanco elanco division lilly focus animal wellbeing animal productivity food safety country company introduced first product veterinary use today offer product elanco employ people country employee worldwide worldwide office country manufacturing plant global headquarters greenfield indiana united state also base u business operation elanco product marketed primarily cattle poultry swine producer elanco companion animal health develops pet medicine assist veterinarian helping companion animal lead longer healthier life lilly corporate responsibility update lorem key ipsum performance indicator key performance indicator goal goal baseline three workplacerelated metric health safety data prior year financial highlight adjusted slightly due updated data collection worldwide revenue million following world resource institute wri guidance progress toward environmental goal reported adjusted basis research development million accounting merger acquisition divestiture appropriate ensure comparability unless stated otherwise goal baseline workplace highlights goal baseline goal cover lillys scope scope emission serious injury rate per employee goal baseline lilly established goal losttime injury rate per employee meeting prior goalto reduce water intake absolute term percent compared four year motorvehicle collision rate collision per million mile driven early water intake used evaluating progress toward waterreduction goal total amount water coming facility including water pumped philanthropy highlight body surface water groundwater water provided utility includes water used process product inkind donation million utility ancillary operation irrigation term include groundwater pumped solely cash contribution million treatment satisfy regulatory action requirement eg remediation activity water used total contribution million another purpose value include water extracted well solely purpose lowering groundwater table maintain physical structural integrity environmental highlights building foundation water intake value adjusted previously reported value due metering energy consumption million btu data evaluation one top water use site energy intensity thousand btussquare foot goal baseline lilly established goal meeting prior goalto reduce waste landfill greenhouse gas emission scope scope metric ton coe percent absolute term compared four year early lillys former current wastetolandfill greenhouse gas emission intensity metric ton coe square foot goal include construction demolition debris biosolids wastewater treatment plant incinerator water intake billion liter ash coal ash reused mine reclamation road base mycelium urea reused fertilizer unlike water intensity million litersmillion revenue energy greenhouse gas emission waterintake goal performance data used calculate progress waste generation metric ton wastetolandfill goal exclude data waste generation intensity metric tonsmillion revenue tippecanoe laboratory facility indiana united state lilly divested waste landfill metric ton data site significant impact worldwide wastetolandfill total reportable permitlimit exceedance reportable permitlimit exceedance environmental release air water land outside regulatory limit necessarily result harm people environment lilly corporate responsibility update conducting business ethically transparently conducting business ethically transparently lilly action grounded core company value integrity excellence respect people business important strive leader corporate responsibility demonstrate value responsible business practice reflect commitment strong governance principle transparency patient customer employee privacy ethical product promotion stakeholder engagement participation public policy process also demonstrates value affect business lilly corporate responsibility update conducting business ethically transparently acting integrity commitment ethic compliance born lillys global anticorruption program component summarizes key principle global company policy commitment integrity policy code overall gecp includes policy procedure provides example employee practice applying business conduct call red book tailored challenge ensuring compliance principle decision action red compliance management system training country market product book designed provide foundational guiding principle program reinforce ethical behavior implemented global anticorruption program help employee navigate increasingly complex every lilly affiliate worldwide internally require global business environment global leader development manufacture training employee anticorruption issue sale pharmaceutical product implemented red book amplified policy standard including bribery continue refine improveprograms procedure accessible employee company designed promote ethical conduct instill culture chief executive officer routinely set tone intranet document govern lillys action compliance train employee ethical top speaking directly employee ethic respect specific area including anticorruption business practice system place detect compliance issue blog audio privacy product promotion safety medical research potential violation law company policy video message global town hall communication security trading record keeping employee meeting international transaction ethical interaction global ethic compliance program gecp take external party interaction government public comprehensive approach compliance includes training communication designed prevent potential code conduct policy standard official payment grant donation meeting procedure healthcare provider gift product sample many issue arising well reporting auditing topic monitoring detect potential compliance failing ethic compliance program include police invested significant resource formal ethic standard procedure communicate key detailed information compliance compliance program include focused effort compliancerelated expectation variety policy practice found corporate privacy anticorruption appropriate product vehicle including red book document responsibility report promotion among area available language emphasizes company value importance ethical decisionmaking lilly corporate responsibility update conducting business ethically transparently advancing public policy transparency lilly lilly committed helping people live longer new pricing model experience taught u transparency healthier active life fulfill mission pharmaceutical industry business model operation help build trust believe important ensure patient access become increasingly challenged payer policymakers needed medication lilly participates public policy stakeholder believe patient pay pocket often believe debate around world contributes policy transparency regarding business practice price newer medicine high environment manner support patient access time company discover develop new involve financial payment physician innovative medicinesleading improved patient medicine experiencing unprecedented price erosion help build trust public outcome since updated position legislated price cut inappropriate reference differential pricing supported research first company announce pricing restriction physician patient contributes policy effort centered patient access would voluntarily disclose choice wealthier country afford innovative innovative medicine medicine increasingly unwilling pay thema public u clinicaltrial resultseven situation exacerbated global financial crisiswhile unfavorable one also first differential pricing developing country cannot afford innovative medicine developedmarket price company report result thirdparty term refers set policy enables differential pricing medicine within country audit database addition publicly new pricing approach needed promote achieves variable price based patient ability access medicine country varying stage report funding provide united pay order balance desire affordable state institution form educational development reward innovative research price lowincome population simultaneously development many barrier grant charitable contribution rewarding medical advance competitive market accessing medicine developing world financial support patient organization price approach facilitates access medicine associated public policy issue lilly engaged support continued research development number leading academic explore topic based europe financial payment benefit patient public private payer u healthcare professional resulting research published journal health pharmaceutical industry effective differential affair outcome effort informs contracted speaker educational pro pricing must supported environment policy engagement global health stakeholder gram provide u advice free reference pricing strategy establishes hope help foster continued dialogue product price point benchmarking price topic resulting research published health company annual political contribution product country prevents affair health affair health affair diversion discounted medicine higherpriced market lilly corporate responsibility update conducting business ethically transparently managing supply chain lilly manage supply chain help maintain supporting pharmaceutical supply safe uninterrupted supply medicine within chain initiative operation broader pharmaceutical early lilly adopted pharmaceutical industry industry work support united nation global principle responsible supply chain management compact principle ensure adherence labor law set forth pharmaceutical supply chain initiative protect environment partner supplier api active pharmaceutical ingredient product psci industry group lilly active around world encourage adopt manufactured lillyowned facility participant psci principle designed align global leadership standard set principle united nation global compact represent highlevel expectation set industry lillys supply chain glance supplier area ethic labor health safety lilly maintains relationship thousand supplier environment related management system material service categorize supplier upon adopting principle lilly revised updated three tier help identify type impact supplier code conduct reflect principle supply risk perspective view current lilly supplier code conduct number pharmaceutical company visit wwwsupplierportallillycomsupplierspages approximately half api active pharmaceutical including lilly shared goal providing conductcodeaspx ingredient product manufactured lillyowned supplier service provider common facility including three site united state well participation psci lilly proud health safety environmental labor ethic site ireland puerto rico united kingdom stand alongside pharmaceutical company business management standard finishing operation including labeling packaging share goal providing supplier service provider take place number site throughout world common health safety environment labor ethic business management standard together industry peer working educate supplier ensure partner operate way consistent company value supply risk risk associated lillys dependence third party either service material critical operation business supply risk come many factor including limited supplier financial stability ability produce provide service quality manner impact natural disaster supplier site risk monitored annual basis mitigation plan implemented monitored minimize lilly corporate responsibility update conducting business ethically transparently lilly fully embrace psci vision part lillys ongoing supply chain risk management lilly supplier type application principle better social economic lilly supplier tier b c must complete annual environmental outcome result involved supplier selfassessment questionnaire available tier pharmaceutical supply chain includes improved audit lillys discretion together supplier provide good service across range condition worker expanded economic development psci company lilly began exploring best way area needed general office functioning cleaner environment local community ensure monitor compliance among supplier includes general office supply travel service member psci lilly committed influencing began conducting supplier audit work ongoing equipment catering routine service positive social environmental change pharma reported depth next report ceutical industry work build supplier tier b capability area supplier diversity supplier provide raw material common commodity used packaging manufacturing learn lillys management environmental lilly also aspires broaden participation small operation includes packaging material waste impact throughout supply chain see fostering diverse business supplier base since disposal service energy environmental sustainability section beginning page u small business administration recognized lilly outstanding effort promote tier c upholding human right maintain supplier diversity goal achieve greater supplier provide active pharmaceutical ingredient percent external spend small including specialty chemical supplier tier lilly maintains longstanding practice complying diverse supplier spent million include active ingredient supplier contract manu local minimumage law requirement diverse supplier exceeding goal million facturers research development lab employ child labor forced compulsory diversesupplier spending labor facility globally lilly began revising global standard procedure include specific language human right supplier data includes data elanco animal health division tier c tier b tier lilly corporate responsibility update conducting business ethically transparently fighting counterfeit medicine european alliance rank among biggest supply chain concern criminal drawn pharmaceutical counterfeiting access safe medicine international pharmaceutical company like lilly prospect high profit low risk offender raising public awareness protecting public counterfeit medicine rarely prosecuted unregulated environment global sale last year estimated high billion full anonymity access patient internet danger posed counterfeit counterfeit medicine big business growing hot spot counterfeiter criminal organization dupe medicine available every part world patient unknowingly customer buying counterfeit medicine fake encountering counterfeit look like actual online pharmacy use image trademarked legitimate supply chain medicine appearance package branded pharmaceutical product internet undertake size color pill dangerous imposter may contain inactive useless ingredientsor lilly actively engaged effort combat counterfeiting major project year lillys partner government others protect even toxic substance arsenic every case health safety patient take medicine muchvalued support help bring counterfeit unreliable case cause harm patient including death lilly founding member steering group participant message wider audience alliance safe online pharmacy broad coalition counterfeit medicine pose real growing threat stakeholder interest protecting patient effect real change patient safety worldwide public health pharmaceutical safety ensuring patient access safe legitimate tremendously proud lilly counterfeiting cross geographic boundary affect online pharmacy europe lilly active european patient suffering variety disease medicine alliance access safe medicine patient stand shouldertoshoulder commonly involved counterfeiting include used education danger counterfeit medicine u important work erectile dysfunction oncology cardiovascular disease mental health preventing proper treatment condition jim thomson chair european alliance access safe medicine source world economic forum global risk sixth edition initiative risk response network january lilly corporate responsibility update enhancing access medicine enhancing access medicine around world estimated least billion people lack access comprehensive health care including medicine treatment tool lilly committed expanding access medicine health care work partner improve health outcome people need putting special focus improving health people low middleincome country around globespecifically tackling several tenacious diseasestuberculosis diabetesthat growing rapidly part world lilly corporate responsibility update enhancing access medicine approach expanding business community access medicine mustplay vital role lilly committed taking thoughtful step meaning map country visit wwwlillycom addressing complex problem fully enhance access medicine improve health responsibilityaccesstomedicinespagesincreasing underserved population however realize accesstomedicinesaspx clear writing check single organization solve problem related donating product alone doesnt access medicine therefore focus effort lasting impact growing believe greatest impact truassist body evidence demonstrates pricing medicine lilly dedicated discovering developing company engages innovative medicine help improve people life lilly strives engage government throughout world offer product sustainable price commitment includes offering assistance people may partner area able afford medicine announced affordable local population price prescription company deep expertise lilly truassist easytouse onestop resource medicine like product differ country country difference currency value access lillys existing patientassistance program vested interest society market dynamicsor may kept artificially low benefit company government price control lilly advocate policy support differential pricingie charging lilly participates partnership prescription enhances performance different price based purchaser ability pay assistance pparx pharmaceutical industry learn work area see page program make easier physician john c lechleiter phd patient access patientassistance program lilly chairman president chief executive officer patent least developed country many developing country lilly seek patient received help enforce patent medicine contribute program percent increase making medicine accessible example previous year program cover range lilly seek patent least developed country health condition including mental health diabetes ldcs defined united nation result cardiovascular disease men health osteoporosis generic manufacturer free produce provide oncology growthhormone disorder market generic version medicine country value assistance provided program totaled million lilly corporate responsibility update enhancing access medicine lilly global health innovation campaign lilly committed partnering closely local government organization identify promote healthcare solution reduce burden diabetes multidrugresistant tuberculosis mdrtb unveiled lilly global health innovation campaign aimed improving health underserved population campaign encompasses two lillys signature program lilly ncd partnership lilly mdrtb partnership create positive longterm change lilly together partner focused researching piloting new model health care based sophisticated research detailed data collection immediately benefit patient reporting sharing data lesson learned locally globally advocating informing key stakeholder program finding encouraging adoption proven solution lilly corporate responsibility update enhancing access medicine lilly ncd partnership noncommunicable disease noncommunicable disease ncds also known mexico afflicting nation community chronic disease include cardiovascular disease mexico lilly work carlos slim health institute family around world diabetes cancer chronic respiratory disease evaluate enhance casalud worldclass primary developing country disease havent garnered care clinic training program centered comprehensive vulnerable bearing attention tuberculosis hivaids ncd diagnosis care lillys role research burden malaria yet together ncds account program demonstrate casalud increased percent death worldwide fourfifths number diagnosed patient andby ensuring early intervention placehas improved prolonged john c lechleiter phd death occur low middleincome country life also measuring cost benefit early lilly chairman president chief executive officer thats lilly created lilly ncd partnership million commitment five year fight growing diagnosis management diabetes sharing burden noncommunicable disease research data program reporting advocacy south africa company government single institution johannesburg africa secondlargest city lilly solve ncd challenge alone take new way working project hope establish hope thinking collaboration unprecedented centre fiveyear communitybased project scale designed identify comprehensive sustainable address care gap people risk already living approach patient care lilly ncd partnership diabetes south vast rural stretch focus initially diabetes targeted community eastern cape partner donald wood india mexico south africa expansion foundation building success homebased brazil late hiv program include improved diabetes care india india lilly joined force public health foundation india population service international project hope implement comprehensive program address low level diabetes awareness uncoor dinated healthcare service project cover people two location sonipat near delhi vizag east coast includes awareness activity healthcare provider training patient care lilly corporate responsibility update enhancing access medicine lilly mdrtb partnership recognizing spread multidrugresistant eli lilly company foundation foundation india tuberculosis mdrtb could halted medicine recently made fiveyear million partnership training program reach pharmacist alone lilly launched lilly mdrtb partnership commitment support organization lilly nurse rural healthcare provider private practitioner according world health organization mdrtb partnership commitment mark several state including andhra pradesh maharashtra people currently infected mdrtb third final phase focus tamil nadu west bengal far diagnosed treated providing training healthcare provider pro russia almost year lilly mdrtb partnership fessional health worker nurse doctor russia partnership research benefit partnership worked world leading informal caregiver community volunteer training healthcare provider demonstrate positive organization battle mdrtb lillys initial contribution improving supply access safe effective effect wellmanaged treatment care included million cash medicine advocacy tool highquality mdrtb drug end health mdrtb patient work take place technology focused prevention diagnosis less percent estimated mdrtb patient region saint petersburg voronezh treatment patient mdrtb nearly million globally received drug needed mari el republic additional fund lilly tb drug discovery initiative accelerate discovery new drug treat tb foundation work partner global local level specific focus partner four south africa weve achieved lot country carrying highest burden mdrtb china south africa partnership support national weve transferred manufacturing technology seven india russia south africa information government plan expand decentralize mdrtb company increase availability mdrtb medicine please visit wwwlillymdrtbcom diagnosis care enhancing healthcare provider capacity investigating current healthcare weve trained healthcare professional china training program variety setting identifying better recognize diagnose treat mdrtb partnership train medical professional six work best replicated well pinpointing weve distributed guideline toolkits need action chinese province namely fujian hebei jiangxi hospital clinic liaoning sichuan xinjiang mdrtb prevention weve reached million people highrisk communi screening tie innovative public awareness campaign lilly corporate responsibility update enhancing access medicine improving access drug treat mdrtb currently far mdrtb patient receive institute medicine iom drug need estimated fewer research project people worldwide receiving verified treatment partnership sponsoring global effort iom drug mdrtb estimated infected assemble leading expert mdrtb evaluate mdrtb range issue contributes challenge effort increase supply mdrtb medicine drug access including poor forecasting product need vet new idea improve access medicine limited laboratory capacity diagnosis underperforming iom convene two meeting current leading thinker market pricing inadequate resource strengthen help ensure mdrtb remains global health priority system needed manage complex treatment regimen required patient partnership work area focus developing new thinking innovation summit translated measureable action partnership hosted innovation summit bring supply chain expert together entrepreneurial collaboration mdrtb advocate thinker inside outside healthcare field look access issue innovative way summit initiative pull together leading expert stakeholder output includes actionable idea addressing barrier field analyze bottleneck access propose best idea pursued collabora solution patient access affordable tions organization working tb field qualityassured treatment lilly corporate responsibility update developing innovative medicine developing innovative medicine year lilly discovered developed acquired innovative new medicine address key unmet medical need worldwide take molecule discovery clinical development commer cialization requires perfect combination promising molecule specialized scientific expertise sufficient funding stage development use medicine lilly strives maintain highest standard ethical behavior begin bioethics program guiding principle reflected commitment protect human right wellbeing clinical research subject well welfare animal research subject lilly corporate responsibility update developing innovative medicine innovation start support commitment speeding lilly innovation fellowship award delivery innovative new medicine patient lilly innovation fellowship award foster postdoctoral launched innovation start global initiative career development selection highly innovation start foster innovation quality innovative research proposal lilly created science institution internal external program broaden postdoctoral scientist training program designed enhance basic science harness experience better prepare broad range innovation aid discovery development career including pharmaceutical industry innovative new medicine patient worldwide award establish precompetitive academic industry two key component initiative include lilly training partnership postdoctoral fellow research award program lilly innovation academic mentor paired lilly scientist provide fellowship award lilly scientist industry resource enable advancement collaborate academic researcher project postdoctoral scientist research proposal aid advancement lillys pipeline future lilly innovation fellowship award invitation applicant academic research center lilly research award program united state united kingdom lilly research award program brings together diverse group scientist worldwide effort advancement research important therapeutic area lilly expertise including neuroscience cancer diabetes immune system disorder others lilly corporate responsibility update developing innovative medicine biopharmaceutical rd highly lilly collaborates help complex formation accelerate development new medicine transcelerate biopharma inc underscore belief lilly often midst clinical study head research development member need competitor medicine comparison company compose tbis board director including way address costly timeconsuming task one jan lundberg phd executive vice president science industrywide challenge vital determining molecule safety efficacy technology president lilly research relation currently available treatmentsespecially laboratory member tbi identified clinical coming together sharing today environment regulator demanding study execution initiative initial area focus best practice ultimate differentiation currently approved medicine five project selected group funding pharmaceutical industry could come together development member company agreed goal accelerating pace develop timely costeffective solution equally share financial commitment personnel information innovative medicine getting necessary comparator medicine risk area including clinical study reach patientswhether development shared user interface investigator new industrywide coalition transcelerate biopharma site portal lilly others inc tbi formed solve challenge others mutual recognition study site qualification training arent possible one pharmaceutical company development riskbased site monitoring approach jan lundberg phd address tbi represents firstofitskind standard executive vice president science technology development consortium pharmaceutical company president lilly research laboratory collaboratingin precompetitive environment lilly development clinical data standard join nine partner founding member tbi establishment comparator drug supply model including abbott laboratory astrazeneca boehringer ingelheim bristolmyers squibb glaxosmithkline johnson johnson pfizer roche sanofi lilly corporate responsibility update developing innovative medicine bioethics bioethics pioneer lilly bioethics program designed address lilly bioethics advisory committee lilly bioethics network lilly one first pharmaceutical increasingly complex ethical challenge global pharmaceutical research development rd beac crossfunctional volunteer committee company establish standing bio today fastpaced biotechnology environment comprising seniorlevel employee area within ethic committee program program promotes ethical research drug development outside rd including medical patient safety today fulltime professional safeguard integrity scientific process discovery research veterinary resource legal corporate affair global brand development membership also staff help promote ethical practice protects patient right wellbeing includes two external academic bioethicists member throughout lilly operation promoting responsible human research take basic training bioethics provide advice bioethics senior leader sat consultation offer input company bioethics purpose lilly bioethics program assist lilly bioethics advisory committee project development lillys official employee identifying addressing bioethical position bioethics issue ben informal issue related lillys rd activity program voluntary virtual community lilly independent organizational unit within lilly employee interested developing fulltime professional staff senior leader knowledge skill bioethics vice president bioethics committed promoting excellence ethic support program also come lilly bioethics advisory committee position consultation beac lilly bioethics network ben development lilly bioethics program comprises four core activity establishing articulating company position bioethics key bioethics issue lilly consulting lilly staff conducting internal education training bioethics education collaboration contributing internal collaborative project inte training grate bioethics rd operation well external project contribute advancement field bioethics relates pharmaceutical application lilly corporate responsibility update developing innovative medicine lillys approach bioethics pharmaceutical research manufacturer informed consent america principle conduct clinical trial one key aspect protecting research participant bioethics framework human biomedical research addition applicable law regulation informedconsent process designed respect lillys ethical commitment beyond legal compliance country country study conducted individual autonomy protect individual lilly strives maintain highest standard ethical choosing location worldwide conduct clinical trial freedom choice patient volunteer wish behavior aspect company business consistent lilly considers local prevalence disease participate lillysponsored research informed brand provide researcher guiding study medical research capability verbally writing purpose method principle practical tool lilly developed bioethics candidate institution possible risk benefit study well fact framework specifically describe evaluate ethic free withdraw study addition lilly work local ethic committee developing conducting analyzing disclosing result time reason decision volunteer andor health authority appropriate ensure study involving human subject framework study must individual choice free undue conducting proposed research location incorporates company value ethic principle widely influence might persuade person consent scientifically ethically justified decision recognized global guideline scholarly literature greater reasonable risk help ensure take consideration lillys policy promise payment money lilly bioethics program member employ bioethics risk benefit research participant reward large unduly influence framework conduct ethical analysis answer relevance research local health need prospective subject decision individual consent consultation question develop bioethics position participate study documented signature potential research yield important agreement case individual protecting research subject right clinical trial scientific advance capable giving informed consent including child lilly place paramount importance safety intent register drug host country consent legally authorized representative may wellbeing individual research participant obtained behalf individual provided bioethics framework basis single global study participant provides assent participate standard lilly applies conduct clinical trial worldwide practice consistent lilly corporate responsibility update developing innovative medicine summary lillys position use placebo control lilly global quality lilly belief use placebo control stem cell research organization development new medicine scientifically lilly belief scientific potential stem cell valuable ethically justifiable provided use research also acknowledges conflicting lillys global quality team independent placebo meet several key condition decision view ethic using stem cell derived conduct placebocontrolled trial made careful organization within lilly comprising certain source support scientific innovation respect analysis scientific ethical consideration risk individual including scientist human life respect stakeholder view lilly u research participant local regulatory requirement stem cell derived animal pharmacist technical quality human source appropriate informed consent professional team involved compassionate use investigational medicine andor assent obtained little risk compassionate use refers authorized use entire lifecycle molecule develop harm sample donor medicine still investigational phase working across phase drug develop development typically treat serious lifethreatening human biological sample ment team goal provide effective disease lilly develops medicinespecific guideline human biological sample long utilized guidance quality oversight collaborating request may considered general lilly preclinical clinical pharmaceutical research authorizes compassionateuse program based colleague research development play increasingly important role posthuman investigational medicine phase development benefitrisk manufacturing assure regulatory genome era specifically dna sample essential profile probability timing regulatory approval understanding genome variation affect lillys quality standard control affected pharmaceutical intervention information lilly bioethics visit followed individualized information extracted wwwlillycomresponsibilitymedicinedevelopment dna sample lilly commits protecting using pagesbioethicsprogramaspx data derived sample responsible manner minimizes potential physical dignatory discriminatory stigmatizing harm lilly corporate responsibility update developing innovative medicine lilly quality putting integrated global quality system patient center quality process fully integrated every stage drug development design phase everything delivery phase monitoring phase lilly known superior qualityin clinical trial product information provide customer producing quality medicine chief responsibility protects bond trust lilly customer every day work make sound decision consistent current regulation science best interest patient goal always carefully listen patient customer respond continuous improvement meet expectation quality lillys hallmark quality team update manages lilly quality design deliver monitor system providing foundational quality requirement clinical development safety efficacy data safety process throughout product development cycle product development manufacturing distribution product complaint integrated structure standard business process organizational management control lilly quality market research product information patient experience system designed assure highquality medicine information get every patient every time system harmonizes quality approach needed among internal external contract manufacturer lilly medicine provides overall quality direction across company ensure able meet standard lillys quality organization provides onsite support well conduct annual riskbased audit plan oversee internal lilly external partner operation audit result provide u knowledge need continue make improvement quality control system lilly corporate responsibility update developing innovative medicine global manufacturing diversity clinical trial individual site work lillys study must designed conducted due minority population historically consistently global manufacturing organization group consideration relevance study human underrepresented clinical trial result responsible company safe production animal health advancement knowledge important information medicine work continuous supply highquality medicine patient animal must provided living condition minority population always available issue worldwide global manufacturing partner lillys appropriate specie contribute critical patient response medicine business area help deliver value health wellbeing vary ethnicity lifestyle genetic background commitment scientific excellence quality cost personnel care animal design help boost enrollment diverse population trial effectiveness integrity maintain continuous conduct animal study must appropriately qualified make trial accessible minority community improvement manufacturing consistently invests trained lilly partnered professional advocacy people process technology needed ensure animal must treated humanely pain organization launch awareness campaign set quality people expect select lilly product distress eliminated minimized goal across therapeutic product line achieve greater diversity among patient enrolling new clinical animal testing performed consideration trial since introduced nearly new animal care use three r replace animal whenever scientifically clinicaltrial site united state location valid acceptable alternative exit reduce minority patient population percent lilly believe moral ethical scientific number animal used refine procedure responsibility ensure welfare animal used minimize distress outreach included multiple presentation purpose company policy standard need diversity clinical trial organization study involving animal must designed regarding use animal based upon u national medical association nma national conducted accordance applicable government principle utilization care hispanic medical association nhma american country local regulatory guidance vertebrate animal used testing research training medical association ama education network intent lilly facility accredited advance cancer clinical trial enacct ama assess potential safety toxicity efficacy association assessment accreditation commission end health care disparity compound human use lilly researcher must laboratory animal care aaalac aaalac provides american association cancer research aacr conduct vivo study acceptable alternative independent review confirmation appropriate also conducted several national regional local exist conducting assessment animal care use united state lillys animal panel reaching journalist advocate healthcare personnel must comply policy care use committee approve oversee animal provider concerning healthcare disparity following principle use similarly lillys ethical committee review animal clinicaltrial diversity strategy usage united kingdom lilly corporate responsibility update developing innovative medicine breaking barrier diverse clinical trial help address barrier access trial clinicaltrial diversity strategy includes following activity translating patient material spanish providing physician education material include background different need distinct patient group partnering advocacy organization raise awareness health disparity need diversity clinical trial actively recruiting investigator diverse patient population lilly corporate responsibility update developing innovative medicine lilly diversity clinical trial united states need diverse representation clinical trial gain insight making medicine effective people use lilly aim better match demographic composition clinical test group disease prevalence rate general population site west site northeast site midwest site southeast site southwest site alaska hawaii site puerto rico site diverse clinical site defined clinicaltrial site patient population medical practice necessarily enroll trial percent noncaucasian lilly corporate responsibility update developing innovative medicine tailored therapy educating patient lillys goal help improve historically medicine one size fit regulatory agency approves medicine individual patient outcome increasingly changing tailored therapeutic concluded overall public medication medicine dont work promise deliver greater precision higher value benefit outweigh risk condition outlined improved outcome individual patient using product label still accurate uptodate safety everyone need variety approach detect meaningful difference information critical healthcare provider understand medicine within patient population identify right drug patient best decide medication right dose patient used lillys role risk management center work safety profile tailored therapeutic part technical using helping healthcare provider make informed decision patient likely take medicine used emerging technology capability pharma monitor patient potential adverse event culture ceutical industry move toward better predictable patient outcome also strategy communicate patient proper use strongly influence patient medication january lilly launched patient enhancing social value medicine medicine safety website wwwlillycomproductspatientsafety define health perception lifestyle potential risk benefit tailoring allows u use realworld data information input educate key external stakeholder role choice healthcare seeking pharmaceutical industry fda physician patient closest patient develop therapy offer play ensuring medicine safe effective behavior need understand value individual society relevant cultural difference impact patient outcome global patient safety coleman obasaju md phd lillys global patient safety organization team senior medical director lilly oncology individual including physician pharmacist global leader diversity clinical research nurse drugsafety professional group lead company effort report adverse event continuously monitor safety lillys product entire lifecycle including identification change benefitrisk balance lilly corporate responsibility update supporting strong workplace practice supporting strong workplace practice century ago colonel eli lillys vision commitment patient employee community set strong tone company continues today business prospered year peoplepeople talent innovation passion making difference finding treatment stubborn disease people whose talent matched generosity people strong value determination prevail regardless challenge lilly corporate responsibility update supporting strong workplace practice developing workforce colonel lillys valuesintegrity excellence respect business effective leadership essential freedom association peoplecontinue shape practice strive created program activity designed build recognize importance freedom association provide employee engaging rewarding working leadership skill longterm responsibility ensure workplace respect right employee environment built foundation trust believe lilly talent pipeline future lilly join association choosing lilly interacts created workplace fair labor practice think many year advance plan drug pipeline work council union several country outside employee respected contribution need people pipeline united state support body work pharmaceutical company mission effective employee collaboration critical lillys productively vast majority worker make medicine help people live longer healthier success work engage employee globally covered traditional collective active life employee essential u foster promote teamwork even challenging bargaining agreement country accomplishing mission early leader business environment believe important operate government mandate working condition company recognized action speak louder invest employee development program salary increase minimum wage bonus wordsparticularly employee concerned connecting heart abroad program invite number weekly working hour vacation time intellectual capital may modern term employee year volunteer company time overtime rate vary country follow even early lilly management understood two week country people lack access mandate wherever required several knowledge skill lilly people company basic resource including quality health care affiliate employee council meet monthly important asset management discus workforcerelated issue directly impact company policy today offer workforce competitive compensation privacy concern organizational change benefit package provide wide variety opportunity personal growth aim create first industry formally environment employee balance work implement policy protect privacy personal life responsibility provide employee employee genetic information opportunity build career reward personally goal ensuring information cannot professionally helping company advance used discriminate employment vision improve patient outcome benefitrelated decision lilly corporate responsibility update supporting strong workplace practice workplace award frequently ranked one best company world work recent recognition includes following top top best place top company diversity best place work work global company leader lilly ranked th best place work hall corporate equality index lilly ranked among top company completed fame working mother magazine aon hewitt diversityinc survey perfect score human partnership fortune second time lilly right campaign index measure rbl group made top list organization effort toward creating equitable environment lesbian gay bisexual transgender lgbt employee top company best class top working family employer asian pacific company american professional finalist lilly cited model workplace flexibility employee workplace executive woman asia society diversityinc national association female executive excellence award finalist equal lilly corporate responsibility update supporting strong workplace practice top company working family diversityinc named lilly top company globally lilly offer number program varying working family diversity assessment firm honor location assist employee maintaining worklife select group company year leadership flexibility include flexible work arrangement innovative solution demonstrate next wave personal leaf onsite health servicesfitness center diversitymanagement success particular lilly well onsite child care credit union dry cleaner honored model workplace flexibility family support program employee lilly flexibility able recruit retain best talent competitive marketplace preparing changing environment reducing cost related lilly recognizes critical importance absenteeism employee flexible work schedule worklife integration tool address lead reduced stress better health stronger diverse need expectation lifestyle focus work overall flexibility lead improved level work style employee allowing employee engagement drive productivity effective john c lechleiter phd lilly chairman president chief executive officer lilly corporate responsibility update supporting strong workplace practice diversity inclusion u workforce lilly embracing diversity core longheld disparity address unique healthcare need value respect people lens community diversity commitment extends understand respond unique need full spectrum business including million individual depend medicine clinicaltrial strategy supply chain proud diversity essential role play helping u accomplish mission making medicine working embed diversity within culture lilly integrating every aspect help people live longer healthier active life businessfrom marketing practice hire creating maintaining nondiscriminatory work employeesand seeing good result example global workforce environment key priority u lilly code twice named diversityincs list top business conduct call red book company diversity widely recognized requires employee behave workplace free improper conduct harassment premiere thirdparty diversity assessment united state list lilly ranked th inappropriate form discrimination company completed survey diversityinc also red book see page lilly employee cited lilly model workplace flexibility embracing diversity mean understanding respecting employee see page valuing difference including limited recently stepped diversity inclusion race religion gender sexual orientation work style effort visible businessbased commitment national origin age focus people area global organization minority employee u workforce lilly work attract retain talented employee manufacturing arena example promoting bring varying perspective skill need operate global level diversity foster creativity effort banner make unique make u stronger developing adopting formal creativity drive innovation innovation lead business case diversity inclusion based better patient outcome enhanced business success notion every person every decision count asian latino without diverse idea simply cannot remain viable also increased leader accountability rapidly changing environment partner advocacy group professional society developing diverse talent senior leader perfor mance objective focusing mentoring careerpath community organization public private healthcare planning woman diverse employee globally administrator others help reduce health african american lilly corporate responsibility update supporting strong workplace practice fighting inclusion health safety wellness woman important proactive working legal system ensure protecting health safety employee customer since make community operate open welcoming coming perspective large one foremost priority consistent majority healthcare decision company value respect people lilly indiana employer global diverse workforce established goal reduce employee injury rate family many lillys employee scientist medical doctor percent end compared see data understand meet pharmacist engineer critical page meet injury reduction target weve research development new medicine recruit focused situation pose greatest risk diverse need need make worldwide highly skilled people intensely employee worldwide slip trip fall motor sure everyone opportunity competitive environment excellent employee vehicle collision ergonomic risk ability thrive home state indiana dependent contribute lead goal aggressive aspirational environment welcoming accomplished hoped would change continue raise voice opposition workplace behavior reduction severity eiry robert md proposed indiana constitutional amendment ban injury across global operation end chair lilly womens network vice president lilly biomedicine samesex marriage civil union lilly view reduced rate serious injury proposed amendment harmful overreaching losttime injury percent since motor addition restricting marriage civil union could vehicle collision rate per million mile meanwhile pose challenge extension domestic partner dropped percent time period believe diversity critical benefit amendment harmful lilly seek despite solid progress currently track attract retain great talent detrimental meet reduction innovation inclusion indiana effort life science leader injury prevention effort impeded several diversityinc list top requires critical mass worldclass talent private sector academic institution lilly challenge example health safety program company diversity matured facility emerging market weve prepared continue strong advocacy seen consistent reporting workrelated injury great honor validation unfair language incorporated indiana highest legal document illness globally mean serious injury effort create environment rate declining quickly would like innovation flourish shaun hawkins chief diversity officer lilly corporate responsibility update supporting strong workplace practice goals tonot people getting hurt early formation wellness productivity injury reported greater integrity want team realized mission organization location report injury happen needed mirror call lilly promise part learn incident help avert similar promise commitment making medicine episode future help patient live longer healthier active life need employee family ergonomic improvement key priority u recognition experience individual recent year weve focusing way adjust stress issue challenge others job fit employee rather way reduction serious injury rate around integrating ergonomic design criterion people hear term wellness often capital improvement project within workplace think physical aspect health fitness routinely host training session employee fulfill promise employee thought type job category lilly invested million important broaden view wellness promoting dollar capital project professional service multiple dimension contribute personal implement employee idea improving wellbeing physical financial social career ergonomic condition office laboratory sale fleet community launched fit life set manufacturing plant tool resource help employee better reduction losttime injury rate manage health also identify thing june lilly made renewed investment contribute healthy active life wellbeing employee launch new fit life offering include following free global compensation benefit program including health screening wellbeing assessment plan formation wellness productivity team health coaching access fitness center team direct responsibility u wellness strategy worklife operation health management promotion continued push toward reducing rate employee activity well leaf disability motor vehicle collision involving sale team similar wellness team several spend much time road reduction motor vehicle collision international location motor vehicle safety program thousand lilly sale representative received behindthewheel training goal based baseline serious injury rate defined number workrelated injury illness require medical treatment beyond immediate first aid per employee working fulltime year losttime injury rate reflects severity serious injury equal number serious injury result employee missing least one day work per employee working fulltime year lilly corporate responsibility update supporting strong workplace practice better defensive driver emphasize serious injury rate losttime injury rate motor vehicle collision rate importance maintaining safe operating distance per employee day workday per employee collision per million mile driven vehicle avoiding distraction texting talking cell phone impede focused driving pleased report workrelated employee fatality lilly continues emphasize prevention catastrophic event weve recently begun identification assessment management everyday workplace risk done incorrectly sequence result serious injury death goal goal goal expect standardize evaluation across company next several year want employee healthy productive lilly life outside work robust serious injury accident category losttime injury accident category management system rigorous health safety program emphasis employee engagement serve cornerstone success reducing injury sprainstrainergo risk sprainstrainerg sliptripfall sliptripfall motor vehicle collision motor vehicle collision sprainstrainergonomic risk sliptripfall motor vehicle collision goal baseline three workplacerelated metric health safety data prior year adjusted slightly due updated data collection lilly corporate responsibility update lilly around world lilly around world lilly robust history community involvement believe make impact extends far beyond medicine make many donationsincluding provided eli lilly company foundationfocus improving access medicine quality health care company donates substantial amount product cash every year employee volunteer time skill score charitable cause program animal health division elanco focus hunger relief developing technology needed feed growing world population elanco committed sustainably end hunger family globally partner ship nonprofit heifer international lilly corporate responsibility update lilly around world lilly global community giving million family helped thousand vial philanthropic insulin commitment lilly mdrtb elancos hunger life child partnership commitment subsaharan africa asia china russia south africa india zambia china indonesia south america publicprivate initiative work elanco animal health division committed donating tackle multidrugresistant tuber committed end hunger vial insulin culosis highburden country familiesor individualsglob international diabetes federation phase iii launched ally partnership life child program million philanthropic commitment heifer international end end five year eli lilly nearly family helped lilly donated nearly vial company foundation help child access diabetes treatment lilly ambassador million thousand five year contributed charitable contribution disaster relief global day service lilly ncd partnership connecting heart abroad global giving project worldwide gave approximately annual global day service brazil india mexico asia africa central guatemala haiti thailand gave million donation among largest singleday south africa south america turkey zambia million charitable contribution following natural disaster volunteer initiative u including cash product company logged lilly ncd partnership launched signature connecting heart eli lilly company foundation inkind donation organization volunteer hour provides million abroad program sends lilly nearly lilly employee around world plus country indianapolis five year fight rising burden ambassador year twoweek contributed planted tree noncommunicable disease ncds assignment provide assistance support global giving applied gallon paint developing nation developing community project country around world program captured page represent biggest philanthropic initiative detail community effort found cr report lilly corporate responsibility update lilly around world community giving united state million educationfocused grant additional meal teacher supported pound watermelon improve public education served financially strategically grown harvested mind trust grant childhood hunger initiative stem program golden harvest indianapolis indianapolis indiana augusta georgia largestever educationfocused grant elanco actively engages support lilly financially strategically supporting elanco employee grew harvested million mind trust helping improve indianapolis childhood hunger initiative implementation indiana science initiative pound watermelon pound public education underserved child elancos help additional meal home state supporting teacher pumpkin land owned managed elanco indianapolis program teach served serving student lilly augusta benefit golden harvest local food bank america novel charter school incubator science coach programa volunteer program reinforcing inquirybased learningtrained lilly scientist matched teacher marion county lilly corporate responsibility update engaging patient engaging patient understand health challenge patient family face provide hundred million dollar product donation year help product contribution tell part story lilly work go beyond medicine help patient improve health manage disease believe informed patient better participant care achieve better health outcome patient access less information lilly corporate responsibility lilly corporate responsibility update engaging patient supporting patient support partner numerous local oncology canvas type diabetes national organization including addressing lilly oncology canvas expression cancer collaboration disney multicultural health disparity improve patient journey art competition exhibition honor child diagnosis type diabetes care united state example minority group journey people face confronted cancer whelming caregiver often question ever often suffer heightened rate certain disease diagnosis biennial competition invite individual able get family back kind daily including diabetes one area therapeutic diagnosed type canceras well family routine parent child may feel diagnosis focus u preventionrelated intervention friend caregiver healthcare providersto end future hope dream customer include material printed multiple language express art narrative lifeaffirming understanding served foundation lilly traditionally underserved community change give cancer journey meaning diabetes business unit partner one everyone need medicine able result compelling art collection provides powerful brand world disney launched get united state lilly truassist insight wide range emotion experienced collaboration offer healthcare provider family wwwlillytruassistcom provides access product touched cancer variety fun informative book child eligible patient several patientassistance tweens including coco first disney character program majority product donation face diabetes campaign lilly disney also offer dynamic content made truassist serf umbrella provides support practical everyday tip family fearless african american connected program lillys many patientassistance effort response customer date empowered face diabetes campaign grassroots program typically focus core area expertise overwhelmingly positive collaboration movement help african american overcome key including cancer diabetes mental illness support expanded multiple international market barrier success living type diabetes african many initiative including following example american disproportionately affected disease according american diabetes association african american united state time likely diabetes nonhispanic white onequarter african american age disease supported lilly face diabetes campaign offer program tool help people make lifestyle change manage disease lilly corporate responsibility update engaging patient diabetes conversation reintegration award scholarship created healthy interaction collaboration founded lilly reintegration scholarship international diabetes federation lilly diabetes program help person bipolar disorder sponsor diabetes conversation program featuring schizophrenia related schizophreniaspectrum conversation map education tool innovative disorder providing funding tuition lab fee education method u unique visual approach book may pursue achieve educational facilitate interactive group participation empower vocational goal independent judging panel people diabetes become actively involved comprised psychiatric care professional review managing disease education tool available application chooses qualifying scholar language launched country since lilly better health lilly better health patientfocused resource camp care package available community health advocacy organization decade lilly one public private healthcare provider policymakers largest provider insulin glucagon educational others interested improving health wellbeing material volunteer scholarship special guest community lilly better health includes diabetes camp comprehensive lilly camp website conference exhibit printed material care package diabetes camp participated reach ten thousand customer directly camp color program arttherapybased year community event program healthcare initiative child requesting camp received conference offering valuable education material million insulin product educational interactive assessment tool variety health topic bookpacks lilly also provides camp tuition support distributed patienteducation partnership american diabetes association resource individual organization website updated spotlight lilly partnership program focus wellness prevention disease management offer ondemand access health education material many lilly better health resource available english spanish select tool mandarin lilly corporate responsibility update fostering environmental sustainability fostering environmental sustainability medicine make require use valuable resource including energy water raw material operate business today longlasting impact lilly take broad approach understanding managing envi ronmental impact across product life cycle committed conducting business patientcentered environmentally socially financially responsible manner lilly corporate responsibility update fostering environmental sustainability commitment approach performance meeting environmental goal demonstrates commitment reduce million million environmental footprint believe implementing innovative costeffective sustainable solution return realized lilly approximate cumulative reduction powerful ongoing source business value project implemented far energy spending helping section cover broad range environmental energy waste natural resource lilly avoid nearly metric ton activity approach management system reduction fund coe emission work addressing environmental issue across business performance data example illustrating progress million liter amount water saved per year number site globally reported zero speke united kingdom manufacturing landfill status facility following enhancement antibiotic production process site may achieve zero landfill status less generated waste sent landfill lilly corporate responsibility update fostering environmental sustainability life cycle approach stage pharmaceutical product life cycle includes distinct environmental health safety impact offer opportunity research development material natural resource manufacturing improvement graphic provides consider environmental factor lilly customer government worldwide measuring reporting reducing lillys overview work reduce potential earliest stage design development increasingly focused material environmental impact manufacturing impact operation design environment initiative include chemical used make product work central company environmental green chemistry environmental productrisk consume less material water sustainability program manufacturing assessment environmental devel natural resource possible health safety environment hse com opment review process evaluate potential mittee oversees compliance applicable environmental issue opportunity hse regulation policy procedure scaleup medicine production standard making certain manufacturing level see page drive continuous improvement throughout information manufacturing organization see page information sale marketing product transport packaging product use product endoflife lilly continually work improve fuel lillys packaging guidelineswhich cover lilly committed understanding medicine intended used efficiency sale force vehicle meet area reducing material use using potential effect pharmaceutical product entirety patient unused medicine internal target reduce overall fleet lowerimpact material enhancing environment well human cannot recycled result model fuel use percent globally lilly packaging recyclabilityhelp u incorporate support using sciencebased evaluation take back reuse recycling sector sale marketing office worldwide weve sustainability consideration packaging assess reduce environmental risk designed capture value product established project reduce energy use decision track greenhouse gas pharmaceutical product use applied industry increasing employee environmental ghg emission product transportation collaboration industry partner academic working customer partner awareness action distribution vendor work researcher regulatory agency ensure costeffective approach available reduce impact see page continually work understand product endoflife disposal balance information proactively address potential impact environmental risk patient privacy legal production distribution use compliance security see page disposal product see page information information lilly corporate responsibility update fostering environmental sustainability manage environmental issue hse governance audit lillys formal hse governance structure ensures year audit significant portion site policy standard hse issue management integrated companywide globally assess performance following protocol several policy standard define commitment global hse committeewhich includes senior outlined hse standard use riskbased guide effort area executive key area businessensures approach determine site audit reassess proper oversight play central role monitoring site every one five year include external global policy health safety corporate performance ensuring continuous well internal auditor audit conducted environment set environmental expectation related improvement global hse lead team work closely compliance environmental protection global hse committee set appropriate lillys environmental goal people operation metric goal assess company performance setting driving toward communicating progress environmental standard provides detailed oversee compliance hse regulation policy toward hse performance goal central hse requirement establishes core governance procedure standard globally manufacturing management approach requirement manage significant environmental hse committee support effort drive energyrelated aspect operation lilly established six hse performance goal ongoing improvement throughout manufacturing minimize impact environment see page management system standard verification organization executive lead team reduce employee contractor injury corrective action standard define requirement business group well lilly research laboratory goal follow earlier set achieved ahead ensure compliance lilly hse standard applicable lilly corporate center manage governance target date demonstrating drive continuous regulatory requirement external hse hse area improvement see page progress toward standard corporation subscribes health safety goal global engineering standard govern many management system environmental aspect operation lilly business unit hse management system energy use ghg emission aligned management system standard consistent thirdparty standard iso product stewardship standard provides ohsas american chemical council systematic way manage product process risk responsible care management system rcms supply chain operation global hse management system also certified use product rcms several lilly facility obtained certification external standard lilly corporate responsibility update fostering environmental sustainability goal baseline energy waste natural resource reduction fund making capital investment technology physical plant operation substantial positive envi ronmental impact however project compete reduction energy intensity reduction greenhouse gas emission intensity funding essential project facility progress address challenge established energy waste reduction progress natural resource reduction fund fund help reduction pay capital project facility globally promotes development environmentally superior efficient technology bestpractice sharing across facility amount spent decreased substantially see table due readily available capital site level shortage needed human resource implement project however fund ontarget invest million lilly realized return million project reduction water intake reduction waste landfill implemented far achieved four year early achieved four year early energy waste natural resource progress progress reduction fund expenditure reduction reduction million updated goal baseline updated goal baseline reduce water intake reduce waste landfill per square foot facility space goal cover lillys scope scope emission following world resource institute guidance progress toward environmental goal reported adjusted basis accounting merger acquisition divestiture appropriate ensure comparability unless stated otherwise absolute term lillys former current wastetolandfill goal include construction demolition debris biosolids wastewater treatment plant incinerator ash coal ash reused mine reclamation road base mycelium urea reused fertilizer lilly corporate responsibility update fostering environmental sustainability product stewardship lilly take broad approach understanding lillys approach green chemistry twofold seek managing hse impact across product life ongoing improvement reducing amount scope health safety environment data cycle see page product stewardship standard hazardous material used make product increasing section set expectation address sustainability material efficiency evaluating chemical alternative stage avoiding riskiest substance also pursue data section cover lillys global fundamental changesthat yield orderof operation including whollyowned subsidiary focus following area magnitude improvementsby advancing state unless stated otherwise using green chemistry design environment art chemistry developing implementing new reduce hazardous material use product development following world resource institute guidance reactor technology manufacturing performance data progress toward envi developed several continuous process ronmental goal reported adjusted decreasing environmental impact product basis accounting merger acquisition improve environmental performance enhance manufacturing see performance operation divestiture appropriate ensure process safety reducing operational scale page comparability unless stated otherwise hazardous manufacturing step one reducing environmental impact packaging hundredfold example lilly scientist recently year calendar year unless stated otherwise using sciencebased environmental risk assessment published article green chemistry journal see evaluate potential impact product detail demonstrating new type grignard reaction environment related edivoxetine hydrochloride production innovation reduces process mass intensity disposing product responsibly endoflife percent decrease amount magnesium diisobutylaluminium hydride required innovation green chemistry percent early lilly one first pharmaceutical lilly also key contributor pharmaceutical company use green chemistry transform roundtable cochairs work group green manufacturing process safer efficient chemistry one focus area developing environmentally friendly research grant produce safer solvent also contributed creation public release harmonized solvent selection guide organization capitalizes several company best practice lilly corporate responsibility update fostering environmental sustainability packaging pharmaceutical environment product endoflife pharmaceutical packaging highly regulated lilly committed understanding potential effect patient dont finish medication must serve many function including protecting product pharmaceutical residue environment using safely dispose reuse recycling unused medicine integrity transit storage providing information improved testing technology scientist location safe option patient help address issue resisting counterfeiting protecting content around world detected trace amount certain support nationally sanctioned disposal guideline tampering access child sustainable pharmaceutical product stream river reported unused medicine united state also promote packaging effort continually review packaging concentration extremely low ranging public education proper drug disposal example technology practice reduce amount part per trillion part per billion world lilly supporter smarxt disposal consumer packaging used utilize lowerimpact material health organization evaluated selected investigation education program sponsored u fish reuse recycle packaging throughout supply chain conducted australia united kingdom united wildlife service american pharmacist association recent year weve saved thousand metric state case found pharmaceutical pharmaceutical research manufacturer ton packaging million dollar present drinking water concentration generally america phrma see lillys position disposal effort also collaborating distributor less time minimum therapeutic unused medicine united state retail pharmacy healthcare provider better well acceptable daily intake drinking water also support proper disposal syrinx needle understand overall pharmaceutical packaging equivalent level according level suggest sharp used home setting mitigate footprint way reduce significant adverse human health impact highly potential public health environmental risk based unlikely exposure drinking water testing feedback patient healthcare provider packaging innovation fegersheim france continues impact persistent ecotoxicity believe education offer greatest opportunity lillys manufacturing site fegersheim france aquatic life optimal path forward address improve sharp disposal practice working replaced disposable cardboard packaging wood issue subject ongoing debate effectively communicate information pallet reusable plastic packaging pallet meet regulatory requirement internal lilly patient product user manual patient education decreased related waste percent equivalent standard assess medicine potential program improved sale force awareness metric ton yearly environmental effect launching new product updated information lilly answer center learn regularly update testing protocol new wwwlillycom existing pharmaceutical knowledge testing method improve continue collaborate regulatory academic research organization advance knowledge area see lillys position pharmaceutical environment world health organization pharmaceutical drinkingwater isbn available web site wwwwhoint lilly corporate responsibility update fostering environmental sustainability performance operation progress toward goalenergy use committed continually improving environmental energy use greenhouse performance across lillys operation includes gas emission thousand btussquare foot significant area environmental impactenergy reducing energy use ghg emission improves use ghg emission water use waste environmental performance decrease one also committed making progress green million btu substantial operational cost research goal procurement reducing nonghg air emission supporting manufacturing distribution activity biodiversity effort community operate maintaining compliance applicable legal since conducted energy assessment standard fundamental part approach energyintensive site uncovered estimated establish work toward share progress million potential annual saving finding hse performance goal see page contributed approximately million cumulative reduction energy spending see information commitment helping u avoid nearly metric ton environmental sustainability direct energy indirect energy energy intensity carbon dioxide equivalent coe ghg emission consumption consumption time period lilly climate change several facility use renewable energy diversify energy source decrease ghg emission climate change issue compelling cogeneration involves using onsite engine government company citizen act generate electricity well recovering usable heat however believe pose significant another important part approach currently risk opportunity business current anticipated regulatory requirement use two site worldwide another one planned financial implication lilly account routine business planning anticipate impact business strategy lilly corporate responsibility update fostering environmental sustainability lillys energy use totaled million meet required condition effort enabled progress toward goalghg emission btu percent less see graph page site reduce electricity use percent gas since energy intensity per square foot facility use percent compared save metric ton coe square foot space improved percent keeping u track nearly per year facility also decreased meet company goal percent improvement coe emission year metric ton decrease energy consumed water use metric ton coe equivalent energy used annually goal approximately average u home water becoming important issue lilly due trend availability quality cost consume company scope scope ghg emission equaled metric ton coe percent water primarily manufacturing production less see graph right due primarily parenteral operation require exceptionally highquality water produce injectable medicine also use reduced energy usage lillys ghg emission intensity improved percent compared keeping substantial amount water support utility u track meet company goal percent site updated waterless cooling system improvement others installed technology reclaims water scope scope greenhouse gas purpose lesser extent also consume emission intensity lilly also calculates scope ghg emission included water domestic u office cafeteria summary data table page included bathroom landscaping graph right progress toward goalwater intake used world business council see lillys recent carbon disclosure project submission sustainable development global water tool additional detail company approach united nation environment programme vital water performance graphic tool refine evaluation waterstressed area operate although determined possible optimizing hvac use alcobendas spain billion liter impact minimal require facility use heating ventilation air conditioning hvac local businesscontinuity plan generated equipment represents percent energy use risk assessment source business interruption alcobendas spain facility save resource including water availability site optimized system setting enabled equipment enter lowenergy mode fresh air following world resource institute guidance progress toward environmental goal reported adjusted basis accounting merger acquisition divestiture appropriate ensure comparability unless stated otherwise goal goal cover lillys scope scope emission updated lilly corporate responsibility update fostering environmental sustainability manufacturing administration group well total waste generation increased percent progress toward goalwaste generation lilly research laboratory implemented plan metric ton see graph right reduce water consumption measure progress largely due increased insulin production target contribute overall water use reduction indianapolis puerto rico plant metric tonsmillion revenue goal assist site identifying watersaving year lilly sent metric ton waste landfill technology financing metric ton percent less see graph right lillys water intake billion liter metric ton percent increase see graph page reduction total waste generated primarily due increased production water equivalent amount waste produced intensity per unit revenue improved percent year u resident period decrease water intake sale marketing equivalent water consumed year city approximately people recently implemented green quest scorecard hazardous nonhazardous waste generation sale marketing site america waste generation waste generation intensity waste canada europe identify score progress toward reducing energy use water consumption lilly u following hierarchy waste treatment transportation year affiliate look progress toward goalwaste landfill eliminate reduce amount waste produced opportunity enhance environmental performance identifying planning new reuse material possible often multiple time project setting target recycle used material make new product recover energy waste treat waste reduce toxicity volume metric ton send waste landfill option feasible water intake total amount water coming facility including water pumped body surface water groundwater water provided utility includes water used process utility ancillary operation irrigation term include groundwater pumped solely treatment satisfy regulatory action requirement eg remediation activity water used another purpose value include water goal extracted well solely purpose lowering groundwater table maintain physical structural integrity building foundation water intake updated value adjusted previously reported value due metering data evaluation one top water use site lilly corporate responsibility update fostering environmental sustainability driving process innovation speke example include following united kingdom guayama puerto rico facility maintains speke united kingdom manufacturing facility acre within ground ecological habitat antibiotic production process require substantial conservation area help preserve restore amount water steam natural resource vibrant plant life country space divided last year collaborated three area focus education reforestation external partner develop test enhancement preservation substantially improved efficiency site augusta georgia united state manufacturing process separate solid within waste stream site manages acre farm burke county enhancing capability handle highly variable facility wildlife habitat committee focus enhancing feed input innovation decreased water usage biodiversity site implementation million liter per year percent total wildlife management plan usage site reducing steam metric ton percent overall use facility clinton indiana united state early change saved projected introduced project showcase compatibility waste stream reduction related initiative could conservation farming protecting push annual saving million acre manufacturing facility location conservation easement forever protect biodiversity land lilly long history working collaboratively believe lilly operation limited impact protect habitat reduce impact operation biodiversity example commissioned ecosystem pursue decentralized approach longterm study kinsale harbour near manufacturing recognizing biodiversity challenge opportunity site southern ireland study ongoing since vary based location engage conservation suggested minor change observed project habitat enhancement many site aquatic life kinsale harbour associated natural worldwide also support conservation effort stress storm event rather discharge community facility located effect facility overall harbor ecologic system shown high resilience ability thoroughly handle wastewater discharge lilly corporate responsibility update fostering environmental sustainability environmental compliance routine inspection u environmental award environmental protection agency identified potential recognition lillys policy comply applicable health safety weakness leak detection repair program environment regulation wherever business lilly technology center facility indianapolis indiana believe compliance foundational maintaining addition voluntarily reported state facility righttooperate local community city environmental agency exceeded see page information hse policy annual limit air emission response event standard management system determined implemented numerous corrective action compliance work remedy enhancement environmental program paid situation quickly possible penalty early settle case use environmental capability assessment harm done employee neighbor listed th greenest u company apply statistical processcontrol technique key environment result event environmental compliancerelated process reduce see summary data table page detail number permit exceedance recognition carbonmanagement program united kingdom operation wildlife work certification lilly corporate responsibility update fostering environmental sustainability fostering environmental sustainability summary data table energy use energy consumption million btu energy intensity thousand btussquare foot energy intensity million btusmillion revenue direct energy consumption million btu coal million btu natural gas million btu fuel oil million btu liquid propane million btu indirect energy consumption million btu purchased electricity million btu purchased steam million btu purchased chilled water million btu greenhouse gas emission greenhouse gas emission scope scope metric ton coe scope scope greenhouse gas emission intensity metric ton coe square foot greenhouse gas emission intensity metric ton coemillion revenue scope emission included metric employee business travel personal car taxi rental car rail air travel metric ton coe segment add total due rounding employee commuting metric ton coe energy use greenhouse gas emission except scope wateruse data reported adjusted basis accounting merger acquisition product transportation distribution contracted metric ton coe divestiture data table nonadjusted waste generated operation metric ton coe data include salesforce travel using company vehicle use lilly aircraft product distribution lilly vehicle item nonkyoto compound emission refrigerant vocs etc metric ton coe scope included data lilly corporate responsibility update fostering environmental sustainability water use water intake billion liters municipal billion liter surface billion liter groundwater billion liter water intensity million litersmillion revenue waste waste generation metric ton hazardous waste generation metric ton nonhazardous waste generation metric ton waste generation intensity metric tonsmillion revenue waste disposition beneficially reused metric ton recycled includes incineration energy recovery metric ton treated includes incineration without energy recovery metric ton water intake used evaluating progress toward waterreduction goal total amount water coming facility including water landfilled metric ton pumped body surface water groundwater water provided utility includes water used process utility ancil landfilled related goal metric tons lary operation irrigation term include groundwater pumped solely treatment satisfy regulatory action requirement eg remediation activity water used another purpose air emission value include water extracted well solely purpose volatile organic compound emission metric ton lowering groundwater table maintain physical structural integrity building foundation data breakdown water intake source particulate matter metric ton available prior water intake value adjusted previously reported value due metering data evaluation one top emission metric ton water use site nox emission metric ton former current wastetolandfill goal include construction demolition debris biosolids wastewater treatment plant incinera ozonedepleting substance potential kg cfc equivalent tor ash coal ash reused mine reclamation road base mycelium urea reused fertilizer reportable permitlimit exceedance environmental release air environmental compliance water land outside regulatory limit necessarily result reportable permitlimit exceedances harm people environment significant spill report refers unexpected unintended abnor number significant spill mal unapproved dumping leakage drainage seepage discharge loss substance resulted damage environment ie environmental fine paid human health aquatic life wildlife material event requiring reporting u security exchange commission damage mean actual imminent alteration environment render environment energy waste natural resource reduction fund harmful detrimental injurious expenditure million see page detail lilly corporate responsibility update lorem ipsum united nation global compact index united nation global compact index ungc principle location report principle b usinesses support respect protection internationally proclaimed human right managing supply chain page principle business make sure complicit human right abuse managing supply chain page principle business uphold freedom association effective recognition right collective bargaining supporting strong workplace practice page principle business uphold elimination form forced compulsory labour managing supply chain page principle business uphold effective abolition child labour managing supply chain page principle business uphold elimination discrimination respect employment occupation diversity inclusion page principle business support precautionary approach environmental challenge fostering environmental sustainability page principle business undertake initiative promote greater environmental responsibility fostering environmental sustainability page principle business encourage development diffusion environmentally friendly technology fostering environmental sustainability page principle business work corruption form including extortion bribery conducting business ethically transparently page lilly corporate responsibility update lorem ipsum report report eli lilly company corporate content data report responsibility update report highlight progress externally verified lilly follows structured process initiative since corporate responsibility collect evaluate calculate data report report also serf lillys annual communication ensure appropriateness accuracy consider progress united nation global compact ungc external standard deciding data collect lilly signatory ungc strategic policy report example following guidance world initiative business committed aligning resource institute report progress toward envi operation strategy universally ronmental goal adjusted basis accounting accepted principle area human right labor merger acquisition divestiture appropriate environment anticorruption index ensure comparability unless stated otherwise ungc indicator report found page global health safety environment management information ungc found system certified independent accredited auditor wwwunglobalcompactorg accordance american chemistry council responsible care management system requirement data update contained report focused calendar year include global welcome feedback report help u operation unless otherwise noted also discus improve future report please contact data trend previous year relevant include significant event initiative robert smith occurred first half report senior director corporate responsibility include joint venture partially owned subsidiary president eli lilly company foundation leased facility outsourced operation email phone financial information prepared according robsmithlillycom generally accepted accounting principle gaap united state subject internal accounting control system external thirdparty audit dollar amount given u dollar lilly corporate responsibility update wwwlillycom